Melphalan is under clinical development by Spectrum Pharmaceuticals and currently in Phase II for Primary Systemic Amyloidosis. According to GlobalData, Phase II drugs for Primary Systemic Amyloidosis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Melphalan LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Melphalan (Evomela) is a phenylpropanoic acid derivative, acts as antineoplastic agent. It is formulated as lyophilized powder for solution for intravenous route of administration. Evomela is indicated for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma, for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.
Melphalan (Evomela) is under development for the treatment of light chain amyloidosis undergoing high dose therapy and autologous hematopoietic progenitor cell transplant, relapsed and refractory multiple myeloma and primary systemic amyloidosis.
Spectrum Pharmaceuticals overview
Spectrum Pharmaceuticals (Spectrum) is a biopharma company that acquires, develops, and commercializes novel drug candidates for treatment of cancer. The company’s pipeline products include ROLONTIS, for treatment of chemotherapy-induced neutropenia helps to reduce the frequency of multiplication of tumors. This product is in phase 3 trails.; Poziotinib, an irreversible tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) tumors with various mutations. This product is in phase 2 trials and lead candidate for the organization. The company has R&D facilities in, Massachusetts and California, the US. The company operates in the US, Europe, Japan, and other countries. Spectrum is headquartered in Henderson, Nevada, the US.
For a complete picture of Melphalan’s drug-specific PTSR and LoA scores, buy the report here.